Bad Omen Or Opportunity? Roche’s TIGIT Failure Hits Rivals Hard

Arcus/Gilead Readout Expected Next

After two failures in a row from Roche, the TIGIT hypothesis is looking shaky, but it is too early to write off the class yet.

Roche_HQ
Roche has a lot riding on its SKYSCRAPER studies - and still hopes they will yield benefits for patients. • Source: Roche

The failure of Roche’s frontrunner TIGIT immunotherapy tiragolumab in a second Phase III trial has not only dragged down the Swiss pharma’s prospects, but also the share price of its biotech rivals.

No-one is writing tiragolumab off just yet, but faith in the TIGIT mechanism has been badly dented, and there are...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip